Loading clinical trials...

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. | Clinical Trials | Clareo Health

COMPLETED

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HORMONE RECEPTOR POSITIVE/ HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) Advanced/Metastatic Breast Cancer In Real World Settings

NCT05155566•Pfizer

View on ClinicalTrials.gov

Summary

To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Latin America.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Oncologist or gynecologist.
•Responsible for treating ≥4-10 (depending on country) ABC/MBC patients who meet the eligibility criteria.
•Agrees to participate in the study and complete the case report forms (CRFs) within the data collection period.
•HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
•Received palbociclib as a first line therapy.
•No prior or current enrolment in an interventional clinical trial for ABC/MBC.
•Minimum of six months of follow up data since palbociclib initiation.

Exclusion Criteria

•Qualified less than 2 years ago or more than 35 years ago.
•Participated in observational research for ABC/MBC in the last 3 months.
•Have not prescribed either palbociclib plus fulvestrant or palbociclib plus aromatase inhibitor as first line therapy.

Locations (2)

Pfizer country office

Buenos Aires, Argentina

Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK

Bollington, Chesshire, United Kingdom

Key Dates

Start Date

May 15, 2019

Primary Completion Date

March 12, 2021

Completion Date

March 12, 2021

Last Updated

January 26, 2024

Enrollment

847

ACTUAL participants

Conditions

Breast Cancer Metastatic

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

NCT06878248

Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)+4 more

View study

RECRUITINGPHASE1/PHASE2

Target-specific immunoPET Imaging of Breast Cancer

NCT06715826

Breast CancerBreast Neoplasms+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Inclusion Criteria

Exclusion Criteria

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Target-specific immunoPET Imaging of Breast Cancer

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis